Tufts University School of Medicine, Boston, MA.
Department of Dermatology, Tufts University School of Medicine, Boston, MA.
Am J Dermatopathol. 2022 Jun 1;44(6):e61-e63. doi: 10.1097/DAD.0000000000002150. Epub 2022 Feb 15.
Acantholytic dyskeratosis mimicking Grover disease as a cutaneous manifestation of a side effect to the Moderna (mRNA-1273) COVID vaccine is rare with only one documented case in the literature to date. Herein, we present a case of an eruptive, erythematous, vesiculopapular rash developing in a patient after the Moderna vaccine. Histopathology of a representative biopsy [x2, done 8 weeks apart] of the rash revealed similar histopathologic findings of patchy suprabasal acantholysis with dyskeratotic keratinocytes and an underlying inflammatory infiltrate of lymphocytes and neutrophils. Direct immunofluorescence was negative. In contrast to the only case previously reported in the literature, a confounding feature in our case, was that patient had a medical history significant for Grover disease, which had been successfully treated with complete resolution and seemed to be in remission. Given the temporal relationship of the onset of the rash to vaccine administration, the changes were likely vaccine-related with the caveat that, in light of the medical history, the differential diagnosis includes reactivation of Grover disease by the vaccine as a trigger factor.
棘层松解性角化不良症酷似 Grover 病,为 Moderna(mRNA-1273)COVID 疫苗的皮肤副作用表现,罕见,目前文献中仅有一例报道。在此,我们报告一例爆发性、红斑、水疱性丘疹疹,发生于 Moderna 疫苗接种后患者。皮疹代表性活检(相隔 8 周进行 2 次)的组织病理学显示类似的组织病理学发现,即局灶性棘层松解伴角化不良的角质形成细胞和淋巴细胞与中性粒细胞的炎症浸润。直接免疫荧光为阴性。与文献中之前报道的唯一病例不同,我们的病例中有一个混杂特征,即患者有 Grover 病的病史,该病曾成功治疗并完全缓解,似乎处于缓解期。鉴于皮疹发作与疫苗接种的时间关系,这些变化可能与疫苗相关,但需要注意的是,鉴于该病史,鉴别诊断包括疫苗作为触发因素引起 Grover 病的再激活。